Peptide · Fact sheet

CJC-1295

Also known as CJC-1295 DAC

CJC-1295 is an experimental growth-hormone-pathway peptide, not an FDA-approved medicine. Online names may refer to different molecules or formulations, making claims especially hard to interpret.

Not FDA approvedEarly human evidence

What is CJC-1295?

CJC-1295 is a synthetic analog designed to extend growth hormone-releasing hormone signaling.

The term is used inconsistently online, including products described as with or without a drug-affinity complex (DAC). Evidence about one form should not be silently transferred to another.

Benefits & claims

It is promoted online for body composition, recovery, sleep, or anti-aging.

Those promotional claims extend well beyond the small human research base.

What the evidence supports

  • Early studies observed changes in growth hormone and IGF-1 measures.
  • Changes in a laboratory marker are not proof of improved recovery, muscle growth, sleep, or longevity.
Research areas
  • Growth hormone and IGF-1 levels
  • Pharmacology and tolerability
  • Growth-hormone-pathway effects in early studies

Dosage & frequency

Human study context

Human research on albumin-binding CJC-1295 measured GH and IGF-1 responses. It does not establish a regimen for muscle gain, recovery, or anti-aging.

Single-dose GH pulsatility study

Healthy men age 20–40

Amount
60 or 90 mcg/kg in separate study groups
Frequency
One study dose
Route studied or labeled
Subcutaneous

Hormone sampling research, not a muscle or recovery regimen.

How to read these amounts

An approved regimen belongs to a specific product, indication, and population. A study regimen describes what researchers tested; it does not establish a prescription or a safe self-use protocol. Products, routes, and formulations are not interchangeable. A prescriber uses the full label and individual clinical circumstances.

Personal accounts may describe amounts, schedules and outcomes beyond clinical research. They do not establish a regimen. Read the reported experiences

Formulations, interactions & practical context

Estimated half-life in early human research
5.8–8.1 days for the studied long-acting CJC-1295 formulation.

Formulation differences

  • CJC-1295 with a drug-affinity complex (DAC) is not interchangeable with products marketed as no-DAC or modified GRF(1–29).

Interactions & precautions

  • GH/IGF-1 research does not establish safety with other endocrine treatments; a validated clinical interaction profile is lacking.

What is still unresolved

  • Long-term clinical benefit and safety outside short research studies remain unestablished.

Side effects & risks

  • FDA cites risks including immune reactions, peptide impurities, increased heart rate, and systemic vasodilatory reactions.
  • Human safety data are limited, especially for long-term or repeated use.
  • Unapproved products can add purity, strength, sterility, and labeling risks.

This is a summary of the cited evidence, not a complete product label. A lack of human safety data does not establish safety.

Clinical research

Early human evidence

Small early human studies examined hormone levels and tolerability. They do not establish broad clinical benefits for popular consumer goals.

Studies

Personal experiences

Reports describe what someone noticed. They cannot establish cause, typical results, or how often a side effect happens. Amounts and schedules describe the individual account, not an effective or safe dose. Product identity and strength may be unverified, and missing details are left explicit.

Explore 3 sourced accounts by reported effect.

Energy: reported experiences

Positive account · personal report

Perceived performance and sleep improvements during combined use

A commenter described better energy, sleep, mood, skin and gym recovery while using CJC-1295 with ipamorelin.

Reported use in this account

Product
Products called CJC-1295 and ipamorelin; CJC formulation not stated
Amount
Not specified clearly
Frequency
Not specified clearly
Route
Not specified clearly
Duration
Three-month exposure periods

Other exposures described: Ipamorelin

The DAC formulation was unspecified. Combined exposure, training and self-assessed body composition prevent attribution to long-acting CJC-1295.

Read the original account
Mixed account · personal report

A commonly confused product name in sleep reports

A person reported easier sleep but unwanted daytime sleepiness while using ipamorelin with a product labeled CJC-1295 without DAC.

Reported use in this account

Product
Product called 'CJC-1295 no DAC'; identity not verified
Amount
150 mcg
Frequency
Five days a week
Route
Injection; type not stated
Duration
Three weeks stated; another week number conflicts

Other exposures described: Ipamorelin, reported at 200 mcg

The paired exposures cannot isolate either product, and 'CJC-1295 no DAC' is not proof of the identity of CJC-1295 with DAC. Three weeks are stated, but another week number conflicts, leaving the exact elapsed time unresolved.

Read the product-labeling example

Approval status

CJC-1295 is not FDA approved. FDA has identified limited clinical data and potential safety risks related to compounded products containing CJC-1295.

Early program stopped without approval

A Phase 2 CJC-1295 study in HIV-associated visceral obesity was terminated, and FDA has not approved a CJC-1295 product. The current public record does not show an active approval path.

Approval covers the labeled product, use and population. A trial phase does not establish success; a stopped program is not ongoing research.

Open questions

  • Long-term human safety
  • Whether biomarker changes lead to meaningful health outcomes
  • How product variants differ in exposure and risk
  • Interactions and risks in people with common chronic conditions

Summary

CJC-1295 has a biological rationale and limited early human data, but no FDA-approved use and no strong evidence for the broad benefits commonly advertised online.

Sources

Medical evidence and regulatory sources are listed here. Personal reports are linked separately in the experiences section.

  1. fdaFDA: bulk substances that may present significant safety risks

    FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.

  2. clinical trialsClinicalTrials.gov: CJC-1295 in HIV visceral obesity

    Registry record for a CJC-1295 study in HIV patients with visceral obesity.

  3. pubmedCJC-1295 growth hormone and IGF-1 study

    Early human study of CJC-1295 pharmacology and hormone markers.

  4. pubmedCJC-1295 pulsatile growth hormone study

    Human study reporting effects on growth-hormone pulsatility and IGF-1.

How we assess sources · Suggest a correction